Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Developer: Eli Lilly and Company Classification: Triple Agonist (GIP/GLP-1/Glucagon receptors) Administration: Once-weekly subcutaneous injection Development Status: Phase 3 clinical trials Expected FDA Approval: Q3 2026 to Q1 2027 Developer: Boehringer Ingelheim Classification: Dual Agonist (Glucagon/GLP-1 receptors) Administration: Once-weekly subcutaneous injection Development Status: Phase 3 clinical trials (SYNCHRONIZE program) Regulatory Status: FDA Breakthrough Therapy designation for MASH Retatrutide emerged from Eli Lillys research into multi-receptor agonism
Retatrutide has a half-life of approximately 6 to 8 days
That chapter is over
The patent was issued in 2019 and would provide market protection until 2033, according to the FDAs Orange Book, a listing of patents for approved drugs
US$ 28.64
US$ 26.86
US$ 28.05
US$ 21.36
US$ 26.43
US$ 23.53
US$ 29.58
